Zoldonrasib in Patients With <em>KRAS</em> G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy - Summary - MDSpire
Advertisement
Clinical Guidelines
Feature
Zoldonrasib in Patients With <em>KRAS</em> G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy
The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in some patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were pr...
Zoldonrasib, an investigational KRAS G12D inhibitor, has shown a favorable safety profile and antitumor activity in KRAS G12D-mutated non-small cell lung cancer (NSCLC) patients previously treated with chemotherapy and immunotherapy. Presented by Dr. Jonathan W. Riess at the AACR Annual Meeting 2026, the phase I study highlights a 52% objective response rate among patients followed for a median of 13.1 months. The study emphasizes the potential of zoldonrasib in treating a currently underserved patient population, with further studies needed to validate these findings.
Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...
Early-onset of immune checkpoint inhibitor (ICI)-related myocarditis was associated with an increased risk for myocarditis fatality, according to the results of a study presented at the American Assoc...
